Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.

Cornillie, J; Wozniak, A; Li, H; Gebreyohannes, Y K; Wellens, J; Hompes, D; Debiec-Rychter, M; Sciot, R; Schöffski, P

Cornillie, J; Wozniak, A; Li, H; Gebreyohannes, Y K; Wellens, J; Hompes, D; Debiec-Rychter, M; Sciot, R; Schöffski, P.

Afiliación

Cornillie J; Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven and University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. jasmien.cornillie@uzleuven.be.
Wozniak A; Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven and University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Li H; Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven and University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Gebreyohannes YK; Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven and University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Wellens J; Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven and University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Hompes D; Department of Surgical Oncology, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
Debiec-Rychter M; Department of Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
Sciot R; Department of Pathology, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
Schöffski P; Laboratory of Experimental Oncology, Department of Oncology and Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven and University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.

Clin Transl Oncol ; 22(4): 546-554, 2020 Apr.

Article en En | MEDLINE | ID: mdl-31201607

Asunto(s)

Antineoplásicos/uso terapéutico; Amplificación de Genes; Liposarcoma/tratamiento farmacológico; Compuestos Orgánicos/uso terapéutico; Proteínas Proto-Oncogénicas c-mdm2/antagonistas & inhibidores; Proteínas Proto-Oncogénicas c-mdm2/genética; Proteína p53 Supresora de Tumor/antagonistas & inhibidores; Animales; Antineoplásicos/farmacología; Doxorrubicina/efectos adversos; Doxorrubicina/uso terapéutico; Dosificación de Gen; Humanos; Liposarcoma/genética; Liposarcoma/patología; Ratones; Compuestos Orgánicos/farmacología; Proteína p53 Supresora de Tumor/genética; Ensayos Antitumor por Modelo de Xenoinjerto

Palabras clave

Dedifferentiated liposarcoma; MDM2-TP53 inhibitor; Mouse double minute 2 homolog (MDM2) amplification; Patient-derived xenografts; Tumor protein 53 (TP53)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Compuestos Orgánicos / Amplificación de Genes / Proteína p53 Supresora de Tumor / Proteínas Proto-Oncogénicas c-mdm2 / Liposarcoma / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: Clin Transl Oncol Año: 2020 Tipo del documento: Article País de afiliación: Bélgica

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google